Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Trugman

Showing results (171-180 of 203) with videos related to

Pageof 21
Sort By:
Scientific Reports|September 14, 2013
Probing the interplay between quantum charge fluctuations and magnetic ordering in LuFe2O4J Lee, S A Trugman, C D Batista, et al.
Neurology|August 28, 2024
Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results From the Randomized PRODROME TrialRichard B Lipton, Andrea M Harriott, Julia Y Ma, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 1, 1994
Exclusion of the DYT1 locus in a non-Jewish family with early-onset dystoniaS B Bressman, A L Hunt, G A Heiman, et al.
JAMA Network Open|June 8, 2022
Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical TrialRichard B Lipton, Patricia Pozo-Rosich, Andrew M Blumenfeld, et al.
Neurology|June 26, 2024
Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS TrialPeter J Goadsby, Deborah I Friedman, Dagny Holle-Lee, et al.
Headache|November 21, 2024
Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM studyJessica Ailani, Richard B Lipton, Andrew M Blumenfeld, et al.
Cephalalgia : an International Journal of Headache|August 20, 2025
Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraineSait Ashina, Messoud Ashina, Dagny Holle-Lee, et al.
Nature|September 21, 2018
Hydraulic diversity of forests regulates ecosystem resilience during droughtWilliam R L Anderegg, Alexandra G Konings, Anna T Trugman, et al.
Archives of Neurology|February 15, 2001
Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson diseaseO Rascol, J G Nutt, O Blin, et al.
Physical Review Letters|August 20, 2013
Measurement of two low-temperature energy gaps in the electronic structure of antiferromagnetic USb2 using ultrafast optical spectroscopyJ Qi, T Durakiewicz, S A Trugman, et al.
Pageof 21

Showing results (171-180 of 203) with videos related to

Sort By:
Pageof 21
Scientific Reports|September 14, 2013
Probing the interplay between quantum charge fluctuations and magnetic ordering in LuFe2O4J Lee, S A Trugman, C D Batista, et al.
Neurology|August 28, 2024
Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results From the Randomized PRODROME TrialRichard B Lipton, Andrea M Harriott, Julia Y Ma, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 1, 1994
Exclusion of the DYT1 locus in a non-Jewish family with early-onset dystoniaS B Bressman, A L Hunt, G A Heiman, et al.
JAMA Network Open|June 8, 2022
Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical TrialRichard B Lipton, Patricia Pozo-Rosich, Andrew M Blumenfeld, et al.
Neurology|June 26, 2024
Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS TrialPeter J Goadsby, Deborah I Friedman, Dagny Holle-Lee, et al.
Headache|November 21, 2024
Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM studyJessica Ailani, Richard B Lipton, Andrew M Blumenfeld, et al.
Cephalalgia : an International Journal of Headache|August 20, 2025
Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraineSait Ashina, Messoud Ashina, Dagny Holle-Lee, et al.
Nature|September 21, 2018
Hydraulic diversity of forests regulates ecosystem resilience during droughtWilliam R L Anderegg, Alexandra G Konings, Anna T Trugman, et al.
Archives of Neurology|February 15, 2001
Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson diseaseO Rascol, J G Nutt, O Blin, et al.
Physical Review Letters|August 20, 2013
Measurement of two low-temperature energy gaps in the electronic structure of antiferromagnetic USb2 using ultrafast optical spectroscopyJ Qi, T Durakiewicz, S A Trugman, et al.
Pageof 21